This meta-analysis by Lynne V. McFarland, Ph.D., reviews the efficacy and safety of probiotics in preventing antibiotic-associated diarrhea (AAD) and treating *Clostridium difficile* disease (CDD). AAD is a common complication of antibiotic use, with a high incidence during hospital outbreaks and moderate rates during endemic periods. CDD, often caused by *C. difficile*, can lead to severe complications and increased mortality. Probiotics are proposed as a strategy to restore intestinal microflora and prevent these conditions. The study includes 31 randomized controlled trials, with a focus on the prevention of AAD and treatment of CDD. For AAD, probiotics showed a significant protective effect (pooled relative risk 0.43, 95% CI 0.31-0.58), with a dose-response relationship observed. For CDD, probiotics also demonstrated a significant protective effect (pooled relative risk 0.59, 95% CI 0.41-0.85). Specific probiotic strains, such as *Saccharomyces boulardii* and *Lactobacillus rhamnosus GG*, showed significant efficacy in preventing and treating CDD. Adverse events were rare, with no serious complications reported. The study concludes that probiotics are effective in preventing AAD and treating CDD, but future research should focus on expanding the types of probiotics tested and improving study design and sample size considerations.This meta-analysis by Lynne V. McFarland, Ph.D., reviews the efficacy and safety of probiotics in preventing antibiotic-associated diarrhea (AAD) and treating *Clostridium difficile* disease (CDD). AAD is a common complication of antibiotic use, with a high incidence during hospital outbreaks and moderate rates during endemic periods. CDD, often caused by *C. difficile*, can lead to severe complications and increased mortality. Probiotics are proposed as a strategy to restore intestinal microflora and prevent these conditions. The study includes 31 randomized controlled trials, with a focus on the prevention of AAD and treatment of CDD. For AAD, probiotics showed a significant protective effect (pooled relative risk 0.43, 95% CI 0.31-0.58), with a dose-response relationship observed. For CDD, probiotics also demonstrated a significant protective effect (pooled relative risk 0.59, 95% CI 0.41-0.85). Specific probiotic strains, such as *Saccharomyces boulardii* and *Lactobacillus rhamnosus GG*, showed significant efficacy in preventing and treating CDD. Adverse events were rare, with no serious complications reported. The study concludes that probiotics are effective in preventing AAD and treating CDD, but future research should focus on expanding the types of probiotics tested and improving study design and sample size considerations.